Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 people, all of whom had a condition called primary sclerosing cholangitis (PSC), a disease affecting the bile ducts in the liver. All 10 participants completed the study. The trial was measuring three things: how often unwanted health events (called adverse events) occurred, whether a specific liver enzyme in the blood called alkaline phosphatase dropped by at least half after treatment, and whether the gut microbiome (the community of bacteria living in the digestive system) changed to become more similar to that of the donor. The reported data shows that out of the 10 participants, 8 experienced at least one adverse event of any level of seriousness. Regarding the alkaline phosphatase measure, the reported data shows that 3 out of 10 participants achieved a drop of 50% or more in their levels. For the microbiome outcome, the reported data shows that 8 out of 10 participants showed changes in their gut bacteria that made it more similar to the donor's microbiome after the procedure. It is worth noting that this was a very small study with only 10 participants, so the numbers reflect a limited group of people. No comparison group (such as a placebo group) was included in the reported data, meaning the figures above describe only what was observed in this single group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Primary Biliary Cholangitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have a confirmed diagnosis of Primary Sclerosing Cholangitis (PSC) — a liver condition — along with a diagnosis of inflammatory bowel disease
- Your liver condition has been present for more than 6 months and has been confirmed by specific imaging of the bile ducts (confirm with trial site)
- A specific liver-related blood marker (alkaline phosphatase) is significantly elevated above the normal range (confirm with trial site)
Who may not be able to join:
- Your liver disease has reached an advanced or severe stage
- You are currently pregnant or breastfeeding
- You have taken certain immune-suppressing medications (such as methotrexate, cyclosporine, or tacrolimus) within the past 4 weeks
- You are not able to give informed consent to participate
- You are unable or unwilling to have a colonoscopy procedure under moderate sedation
- You have previously had a Fecal Microbiota Transplant (FMT), which is the treatment being studied in this trial
- You have a confirmed cancer or malignancy
- Your immune system is weakened or compromised for any reason
- You have taken certain specific anti-inflammatory medications (such as infliximab, adalimumab, or vedolizumab) within the last 8 weeks
- You have taken antibiotics within the past 2 months
- You are currently in, or have participated in, another clinical trial within the past 30 days
- You have taken probiotic supplements within the past 30 days
- You have an immune deficiency condition, whether present from birth or developed later in life
- You have certain other health conditions including diabetes, lupus, or chronic kidney disease (confirm with trial site)
- You have a history of heart valve disease, rheumatic heart disease, or endocarditis (an infection of the heart)
- You are taking steroids at a dose greater than 20mg per day
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse Event Frequency; Comparison of Alkaline Phosphatase Pre and Post Transplant
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.